Government hopes spaceport plans will boost biotech research
But trial in patients in early stage of the disease continues.
UK biotech has stake in two potentially lucrative drugs thanks to hybrid business model
Big data initiatives positioning the UK as a desirable location for R&D.
Investment fund kick-starts phase 2 trial in CMML
French biotech developing cancer immunotherapy with BMS.
Other Japanese firms could scale back UK investment.
Make NHS best place to research and launch drugs, says ABPI.